PVI
CTMX icon

Pura Vida Investments’s CytomX Therapeutics CTMX Stock Holding History

Pura Vida Investments’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-96,905
Closed -$420K – 242
2021
Q4 		$420K Sell
96,905
-2,466
-2% -$14.4K 0.02% 214
2021
Q3 		$506K Sell
99,371
-1,470
-1% -$7.87K 0.02% 250
2021
Q2 		$638K Sell
100,841
-101,637
-50% -$791K 0.02% 196
2021
Q1 		$1.56M Buy
+202,478
New +$1.6M 0.04% 173

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Pura Vida Investments's CTMX Position: Q1 2022 in Review

Pura Vida Investments sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 96,905 shares — an estimated $420K sold.

Pura Vida Investments first reported a position in CTMX in Q1 2021 and held it in 4 quarters. The position peaked at $1.56M in Q1 2021. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

  • Pura Vida Investments reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 96,905 CytomX Therapeutics shares in Q1 2022, an estimated $420K.
  • Pura Vida Investments first reported a position in CytomX Therapeutics in Q1 2021 and held it in 4 quarters.
  • Pura Vida Investments's CytomX Therapeutics position peaked at $1.56M in Q1 2021.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.